G&E Herbal Biotechnology , Ltd. EBIT

As of the most recent data (June 2026), 4911.TWO shows a EBIT of $84M. That compares with $160M in the prior-year period — down 46.7% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4911.TWO's EBIT is now $84M (was $160M) — a 46.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether G&E Herbal Biotechnology , Ltd. is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. G&E Herbal Biotechnology , Ltd. is at $84M, which is lower that average. That is roughly 99.6% below the sector mean. Use the comparison chart on this page to see how 4911.TWO stacks up against individual peers as well.

Tracking 4911.TWO's ebit over time shows whether G&E Herbal Biotechnology , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $84M That compares with $160M in the prior-year period — down 46.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has G&E Herbal Biotechnology , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $84M) with ownership activity and broader fundamentals.